Randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of sitagliptin on postprandial plasma lipoprotein concentrations in patients with type 2 diabetes
Phase of Trial: Phase III
Latest Information Update: 29 Dec 2012
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 10 Dec 2012 Actual end date Apr 2009 added as reported by ClinicalTrials.gov.
- 05 Mar 2011 Status changed from recruiting to completed.
- 12 May 2008 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History